Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
No Data
VCEL Transcript
Vericel Corporation (VCEL) Q1 2026 Earnings Call Transcript
Positive5-7
The earnings call summary and Q&A reveal strong financial performance, optimistic guidance, and strategic initiatives like MACI Arthro and international expansion. The Q&A highlights positive sentiment from analysts, with no significant competitive threats and strong growth drivers. The company's expanded sales force and BARDA award further bolster the outlook. Despite some unclear management responses, the overall sentiment is positive, suggesting a stock price increase in the 2% to 8% range.
Vericel Corporation (VCEL) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call reflects strong financial performance with record-high gross and EBITDA margins, significant revenue growth, and a robust cash position. The Q&A highlights positive sentiment towards pricing strategies and surgeon adoption, though some guidance lacks specifics. Despite slightly lower MACI growth guidance for 2026, the overall outlook remains optimistic with ongoing expansion efforts and potential BARDA RFP opportunities. The positive financial metrics and strategic growth initiatives suggest a likely stock price increase in the short term.
Vericel Corporation (VCEL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
Vericel Corporation (VCEL) Q3 2025 Earnings Call Transcript
Positive11-6
The earnings call highlights strong financial performance, with record high operating cash flow and free cash flow, along with positive trends in MACI Arthro demand and surgeon adoption. The Q&A session reveals positive analyst sentiment, with no significant insurance challenges reported. The company's MACI sales force expansion and expected profitability improvements further support a positive outlook. However, cautious guidance for Q4 and lack of specific 2026 projections slightly temper enthusiasm. Overall, the sentiment is positive, with potential for a stock price increase in the 2% to 8% range.
VCEL Slides
Vericel Q1 2026 slides: 30% revenue growth drives guidance raise2026-05-07
Vericel Q4 2025 slides: record margins offset by 2026 guidance2026-02-26
Vericel Q2 2025 slides: MACI drives 21% revenue growth, margins expand2025-07-31
Vericel Q1 2025 slides: record revenue offset by widening losses, raises guidance2025-05-08
VCEL Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
